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Abstract
Radiation-damaged nanodiamonds (NDs) are ideal optical contrast agents for photoacoustic (PA) 
imaging in biological tissues due to their good biocompatibility and high optical absorbance in the 
near-infrared (NIR) range. Acid treated NDs are oxidized to form carboxyl groups on the surface, 
functionalized with polyethylene glycol (PEG) and human epidermal growth factor receptor 2 
(HER2) targeting ligand for breast cancer tumor imaging. Because of the specific binding of the 
ligand conjugated NDs to the HER2-overexpressing murine breast cancer cells (4T1.2 neu), the 
tumor tissues are significantly delineated from the surrounding normal tissue at wavelength of 820 
nm under the PA imaging modality. Moreover, HER2 targeted NDs (HER2-PEG-NDs) result in 
higher accumulation in HER2 positive breast tumors as compared to non-targeted NDs after 
intravenous injection (i.v.). Longer retention time of HER-PEG-NDs is observed in HER2 
overexpressing tumor model than that in negative tumor model (4T1.2). This demonstrates that 
targeting moiety conjugated NDs have great potential for the sensitive detection of cancer tumors 
and provide an attractive delivery strategy for anti-cancer drugs.
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1. INTRODUCTION
Detection of cancerous tumor at an early stage is critical to diagnose cancer accurately, 
initiate treatment effectively, and thus improve patients’ survival.1, 2 Traditional biomedical 
imaging modalities, such as computed tomography (CT) and ultrasound, have been used to 
visualize tumors in the clinic.3–5 However, these techniques suffer from their intrinsic 
disadvantages, such as the relatively low spatial resolution, specificity and contrast, which 
limit their application for providing sufficient functional and molecular information of 
imaging areas. Although the resolution could reach as high as several micrometers with the 
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development of optical imaging techniques, the high optical scattering of biological tissues 
limits their imaging depth to less than a few millimeters, and consequently impedes their 
further in vivo applications. For example, optical fluorescence imaging is capable of 
providing specific molecular information at subcellular resolution, however, this technique 
only allows the imaging at a depth of 1–2 mm.6, 7
Photoacoustic (PA) imaging is an emerging non-invasive and non-ionizing biomedical 
imaging modality combining a high spatial resolution of ultrasound technique and excellent 
contrast of optical imaging with the help of various contrast agents.8–10 Within the 
photoacoustic effect, light is absorbed by either the tissue or exogenous agent in the 
interested tissue and converted to ultrasound via its transient thermal elastic expansion. 
Because acoustic attenuation is 1000 times weaker than that of pure optical imaging when 
traveling in the biological tissue, PA imaging has a great penetration depth up to several 
centimeters with reasonable resolution.11, 12 PA imaging is an absorption-based technique so 
that the biological tissue components having high optical absorbance, such as hemoglobin 
and melanin, which can be used as endogenous contrast agents to image blood vessels, 
hemoglobin oxygenation and tumor angiogenesis.13–16 Without the assistance of exogenous 
contrast agents, PA imaging has shown to be useful in various applications, but cancer 
tumors except melanoma are always transparent and do not absorb light much so differently 
from surrounding normal tissues. The introduction of exogenous contrast agents has greatly 
enhanced imaging sensitivity and specificity.17 Organic dyes, quantum dots (QDs) and 
plasmonic nanoparticles have been widely used in the PA imaging. Among these, contrast 
agents having high optical absorbance in the near-infrared (NIR) region are more attractive 
since the PA signal contribution from normal tissue and hemoglobin is minimum and Mie 
scattering effect is relatively weak within the optical window at the wavelength of 700 to 
1100 nm. In addition to the strong absorption in the NIR range, other properties of contrast 
agents must be considered for the biomedical applications, such as toxicity, size, stability 
and surface chemistry. Some biocompatible dyes, including methylene blue and indocyanine 
green, have been used in PA imaging system. However, organic dyes are so small molecules 
as to be cleared quickly from body through the renal system, and fluorescence suffers from 
the intermittency and photobleaching which limits their further application even though their 
conjugation to nanoparticles makes them have suitable size for passive tumor uptake. The 
most developed PA contrast agents are plamonic nanoparticles due to their tunable and five 
times stronger optical absorption than dyes based on the surface plasmon resonance (SPR) 
effect. Gold nanorods are extensively used in PA imaging because of its relatively simple 
synthesis, even stronger plasmon resonance absorption in the NIR range.18 The great 
advances in surface functionalization encourage its use in tumor imaging.19 However, gold 
nanorods tend to melt and thus deform under strong and longer laser light irradation. 
Although this strategy has been used to release the DNA oligonucleotides, nanoparticles 
were not able to provide consistant PA signals at a specific wavelength during the whole 
imaging process.20, 21 In addition, long-term toxicity of gold nanoparticles has to be 
considered in further applications in clinic.
Owing to the excellent biocompatibility and exceptional optical stability, nanodiamonds 
(NDs) are shown to be outstanding optical contrast agent and drug carriers for biomedical 
applications.22 By introducing nitrogen vacancy center as a fluorophor in the NDs, 
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fluorescent nanodiamonds (FNDs) exhibit competitive advantages over organic fluorescent 
dyes and quantum dots (QDs) due to the long-term stability and non-toxicity as an in vivo 
contrast agent.23–25 Recently, alternative strategy for using nanodiamonds as imaging 
contrast agents have also been reported. Making use of the detectable electron spin 
resonance of nitrogen-vacancy centers, different shapes of nanodiamond targets within the 
chicken breast tissues were imaged with a spatial resolution of ~800 μm.26 Carbon-dots 
(CDs) with tunable and strong photoluminescence produced by hydrothermal oxidation of 
nanodiamonds have been utilized for cell imaging.27 Fabrication of nanodiamonds with 
diethylenetriaminepentaacetic acid (DTPA) - Gd chelate improved the signal intensity on 
T1-weighted magnetic resonance images.28 Non-fluorescent nanodiamonds with ~70 nm in 
diameter employed as a PA imaging agent was firstly proposed in our earlier publication.29 
Since a low fluorescence quantum yield results in more efficient PA signal generation, 
nanodiamonds shown ~70 times stronger PA signals than gold nanorods on a particle molar 
basis.
In this work, we are aiming at diagnosing early stage breast cancer using 35 nm radiation-
damaged nanodiamonds. To enhance the systemic circulation time and particle stability, 
nanodiamonds were firstly surface functionalized with polyethylene glycol (PEG). To 
further enhance the imaging sensitivity and contrast of tumor areas, PEGylated NDs were 
then conjugated to anti-human epidermal growth factor receptor 2 (HER2) targeting peptide, 
KCCSYL.
This six-amino-acid KCCYSL sequence was identified in HER2-positive breast cancer cells 
and exhibited 295 nmol/L affinity to HER2 receptor which enabled its great potential in 
tumor-imaging application.30, 31
2. METHODOLOGY
2.1 Materials and chemicals
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl), N-
Hydroxysuccinimide (NHS), sodium borate, sodium hydroxide, potassium chloride (KCl) 
were purchased from Sigma-Aldrich (St. Louis, MO). Amine-PEG2000-amine was 
purchased from Jenkem Technology (Allen, TX). Fetal bovine serum (FBS) was purchased 
from Fisher Scientific (Pittsbrugh, PA). Dulbecco’s Modified Eagle’s Medium (DMEM) 
was purchased from Lonza (Allendale, NJ). Anti-Human epidermal growth factor receptor 2 
(anti-HER2) peptide (KCCYSL) was provided by Dr. Kun Cheng (University of Missouri-
Kansas City, MO). 4T1.2 breast cancer cells were provided by Beth A. Vorderstrasse 
(Washington State University, WA) and used with the permission of Robin Anderson (Peter 
MacCallum Cancer Centre, East Melbourne, Australia). Deionized (DI) water was used for 
preparing all of the solutions.
2.2 Bioconjugation and characterization
Nanodiamonds were synthesized as we described before.19 The conjugation of amine-PEG-
amine and anti-HER2 peptide with NDs followed a standard EDC/NHS-mediated coupling 
procedure.36, 37 Briefly, 2 mg of NDs were dissolved in 2 mL of sodium borate buffer (10 
mM, pH 8.5), followed by sonication for 30 min. EDC·HCl (4 mg) and NHS (4 mg) were 
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added to the NDs solution, which was stirred at room temperature for 0.5 hr to form the 
amine-reactive NDs intermediates. A 0.5 mL solution of amine-PEG2000-amine (10 mg) 
was finally added to the above solution. After stirring overnight, the amine-PEG-NDs were 
purified by centrifugation at 10,000 × g for 5 min, and particle precipitate was washed three 
times with DI water. To synthesize the HER2-PEG-NDs, the carboxyl terminus of anti-
HER2 peptide (1 mg) was pre-activated by mixing with EDC·HCl (4 mg) and NHS (4 mg) 
for 0.5 hr in DI water, followed by the addition of amine-PEG-NDs (2 mg) aqueous 
solution. As a result, the anti-HER2 peptide was covalently linked to the PEGylated NDs 
after stirring the mixture overnight. The resulting nanoparticles were separated from the 
solution by centrifugation, washed with DI water three times, and dried in SpeedVap 
(Labconco).
Fourier-transform infrared spectroscopy (IRAffinity-1 FTIR Spectrophotometer, Shimazu) 
was conducted to confirm the coating of PEG and anti-HER2 peptide on the NDs. 
Hydrodynamic diameters and zeta potentials of ND particles in aqueous solution were 
determined using ZetaPALS (Brookhaven Instrument Corporation). All measurements were 
carried out in five replicates. The morphology of NDs was determined using high-resolution 
Transmission Electron Microscope (TEM) (FEI Tecnai F20 XT Field Emission TEM), and 
sample was applied on a lacey carbon coated copper grid (TED PELLA).
The optical characterization of the NDs was measured using a same setup as our former 
paper.29 DI water suspension of NDs was injected into Tygon tubing (1 mm ID, 1.78 mm 
OD), which was immersed in the water. The PA amplitude of NDs at different wavelengths 
was recorded with 5 replicates.
2.3 Cell culture and cellular uptake
4T1.2 and 4T1.2 neu breast cancer cells were cultured in DMEM containing 10% FBS and 
1% L-glutamine at 37 °C supplied with 5% CO2 under a humidified environment.
Cells were seeded onto a 12-well culture plate, in which poly L-Lysine precoated glass 
coverslips (BD, Franklin Lakes, NJ) were placed previously, at a density of 50,000 cells per 
well for overnight. 4T1.2 neu cells were treated with or without 32 μg (based on NDs) PEG-
NDs or HER2-PEG-NDs, whereas 4T1.2 cells were treated with or without 32 μg (based on 
NDs) HER2-PEG-NDs followed by incubation at 37 °C for 4 hr. Then the cells were washed 
three times with 3 mL PBS solution and imaged using inverted microscope (Eclipse 
TE2000-U, Nikon).
2.4 Photoacoustic imaging
The experimental setup for PA imaging of biological tissues is shown in Scheme 1. The 
deep reflection-mode PA imaging system is capable of sub 0.2-mm resolution at depths of 
19 mm and penetration of up to 38 mm.38 In this study we used a same configuration as 
described previously.39 A 532-nm Q-switched Nd:YAG laser (Surelite III, Continuum) was 
employed to pump an optical parametric oscillator laser (Surelite OPO PLUS, Continuum) 
with 6-ns pulses and repetition rate of 10 Hz. The laser output was transformed through an 
optical condenser to a ring-shape illumination, which is confocal with ultrasonic transducer 
in the targeted area. The illumination beam had a diameter of 7 mm on the tissue surface, 
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and the laser fluence was 18 mJ cm−2, which was lower than laser safety limits (20 mJ 
cm−2 ) recommended by the American National Standards Institute (ANSI). A 5-MHz 
transducer (35-mm focal length; 70% -6-dB fractional bandwidth, SU-108-013, Sonic 
Concepts) was used to collect the photoacoustic signals, which were amplified by a pre-
amplifier (5072PR, Olympus-NDT) and then collected by a PC through an A/D Scope Card 
(CS21G8-256MS, Gage) with a 125-MHz sampling rate for analyzing and forming PA 
images. Female BALB/c mice were used in the experiments in accordance with the guide 
and supervision of the Institutional Animal Care and Use Committee at University of 
Kansas. The murine breast cancer cells, 4T1.2 and 4T1.2 neu, were prepared in PBS solution 
at a concentration of 2 × 107 cells/mL, and kept in ice bath before injection. Mice were 
under anesthesia with 1.5% isoflurane in 1:1 oxygen-air mixture. 50 μL cell suspension was 
injected subcutaneously into the right mammary fat pad under the nipple of the mice using 
30-ga needles. Mice were ready for PA imaging when the breast cancer tumors had a size of 
~5 × 5 mm.
Before each imaging experiment, the animals were anesthetized with a mixture of ketamine 
(87 mg/kg body weight) and xylazine (13 mg/kg body weight). The right breast areas of 
mice were shaved using standard surgical hair removal lotion to avoid the interference from 
hairs to ultrasound propagation. The mice were maintained under anesthesia on a warm pad, 
and underneath the membrane in the center of the bottom of the water tank during the entire 
imaging process. Between the mouse skin and the membrane, ultrasound gel was applied 
and served as coupling medium. Breath of mice was visually monitored and maintained at 
one breath per two seconds. The PA images of the breast tumor areas were obtained as 
background images before injecting PEG-NDs or HER2-PEG-NDs particles. Once the 
imaging depth (2 – 3 mm) was determined along with the imaging resolution of ~270 μm, 
particles were intravenously administrated into the mice tail vein. The tumor areas were 
scanned continuously and repeatedly by PA system at a laser wavelength of 820 nm.
3. RESULTS AND DISCUSSION
3.1 Synthesis and characterization
In order to verify the successful conjugation of amine-PEG-amine (MW 2000) and anti-
HER2 targeting peptide to the NDs via EDC/NHS mediated reactions, FTIR spectra were 
collected at the end of each step, as shown in Figure 1. The appearance of the characteristic 
peaks, at 1250 and 1035 cm−1, of the PEG confirmed the presence of the coating on the 
surface of bare NDs. In addition, the FTIR spectrum of HER2-PEG-NDs displays same 
intense peaks as anti-HER2 peptide at 1656 and 1521 cm−1 corresponding to the stretching 
vibration of the amino group on lysine and hydroxyl group on tyrosine, respectively. The 
band at 1200–1260 cm−1 resulted from the -OH stretching vibration in the serine. These data 
confirmed the introduction of HER2 targeting peptide onto the NDs with the linkage of 
amine-PEG-amime. ~10% of the carboxyl groups on the NDs are reacted with amine-PEG-
amine, which is assumed similarly as we described before, and then are conjugated with 
anti-HER2 peptide in a 1:1:1 ratio. Yield for the amount of targeting peptide on the surface 
of NDs could be estimated as the order of ~10−5 mol g−1.
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3.2 Morphology and optical properties
In addition to the FTIR, the coating of PEG and HER2 targeting peptide was further 
confirmed by the hydrodynamic diameters and zeta potentials of the NDs and the surface-
functionalized NDs. Table 1 shows the progressive increase in particle sizes and change in 
charge state of the nanoparticle surfaces. The size distribution of nanoparticles was plotted 
in Figure 2. The decrease in the negative charges was due to the introduction of amino 
groups from amine-PEG-amino and lysine residues in anti-HER2 peptides.
The optical absorption characteristic of NDs was plotted as a function of wavelength using 
UV-Vis spectrometer (Figure 3a). The absorption intensity decreased 80% from 450 nm to 
850 nm. Since photoacoustic imaging is an absorption-based technology, the PA signal 
amplitude decreased in proportion to the decline of the optical absorption in the tunable 
wavelength range of PA imaging system. Although the small bump at 720 nm in the 
photoacoustic spectrum is not shown in the UV-Vis absorption spectrum, the signal intensity 
dropped 50% from 700 nm to 840 nm, which had the same tendency as that in absorption 
spectrum.
3.3 Cellular imaging
The targeting ability of anti-HER2 peptide was validated in vitro by the brightfield images 
of HER2 receptor positive and negative breast cancer cells (4T1.2 neu and 4T1.2 cells) 
(Figure 4). As negative controls, 4T1.2 neu breast cancer cells were treated with non-
targeting PEGylated NDs (4T1.2 neu cells + PEG-NDs) and HER2 negative 4T1.2 cells 
were treated with targeting PEGylated NDs (4T1.2 cells + HER2-PEG-NDs). The clusters of 
ND particles present black spots in the cells. There was no obvious accumulations of NDs in 
the control groups after 4-hr incubation (Figure 4b and 4d), whereas a large amount of 
HER2-PEG-NDs were found in the HER2 overexpressing cells (Figure 4e). Moreover, some 
particle clusters were detected in the cell membranes (arrows in the Figure 4), which is not 
seen in Figure 4b and 4d. The phenomenon demonstrates that HER2-PEG-NDs effectively 
bound to the HER2 receptors on the cell membrane and entered cells via receptor-mediated 
endocytosis.
3.4 In vivo PA imaging
The tumor areas of mice bearing breast cancer were imaged under PA imaging system at 
820 nm. Although NDs had stronger absorption and thus higher contrast against background 
tissues at 700 nm comparing to 820 nm, the signal contributions from blood vessel would be 
also greater. Herein, imaging wavelength of 820 nm was chosen because the absorption of 
hemoglobin and Mie scattering is minimized and the PA signal enhancement is more 
specifically in the pictures due to the accumulation of ND particles. Prior to the injection, a 
region of interest (ROI) was selected on the right side of the breast and defined as 
background (BG). Imaging depths were adjusted so as to obtain the best spatial resolution.
BALB/C mice were injected with identical amount of diamond nanoparticles (35 μg on the 
NDs basis) via tail veins. Once the imaging depth is determined, PA images of same areas 
were taken continually with 1-hr intervals and processed to remove the signals from mouse 
skin as illustrated in Figure 5. Of the two control groups, one is HER2 positive tumor model 
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(4T1.2 neu) treated with PEG-NDs (Figure 5a), and the other one is HER2 negative tumor 
model (4T1.2) treated with HER2-PEG-DNDs (Figure 5b). In the PA images, the blood 
vessels (BVs) were highlighted because of the relatively higher optical absorption of 
hemoglobin over normal optical transparent tissues. Beginning at 2nd hour post-injection, 
the blood contrast was enhanced as indicated by the colorbars in the figures, and signal 
intensity reached maximum at the 6th, 4th and 5th hour scanning session of each group. 
Moreover, owing to the enhanced permeability and retention effect, nanoparticles tend to 
leak out from the abnormal vasculature and accumulate in the solid tumor. However, Li 
M.L. etc demonstrated that gold nanoshells could not actually enter the necrotic tissues of 
tumor, but accumulated within the tumor cortex and delineated the tumor contour when the 
nanoshells were detected by PA microscopy under the wavelength of 800nm.33 NDs 
particles progressively migrated from blood vessels toward tumor region and were uptaken 
within breast cancer tumor surface, which was also observed in our PA images. Compared 
to the control groups, HER2 positive breast cancer model treated with HER2-PEG-NDs 
intravenously had higher signal enhancement around the tumor region and finally delineate 
the entire tumor (dashed circle in Figure 5c) at the 8th hour. The presence of NDs within the 
tumor core was not effectively detected because of both the necrotic feature and high 
interstitial pressure of tumor cores.34 In addition, no observation of NDs on the top surface 
of the tumor may be explained by the pressure from water tank above the tumor area 
hindering the particle accumulation. Meanwhile, slight accumulation of nanodiamonds 
appeared in the control groups make it difficult to differentiate the tumor regions without the 
illustration of photographs of ROI. These phenomena demonstrate that the tumor uptake of 
HER2-PEG-NDs is indeed a target-specific event. This result is further confirmed by the 
prolonged retention time within tumors in the HER2 targeting treatment group. The signal 
intensity of tumor region was monitored and compared between two consecutive scanning 
until the decrease in signal amplitude was acquired. As shown in Figure 5d, the signal 
decrease was found after the 8th hour on average in Group 3, whereas in Group 1 and 2, the 
Tmax at ~ 6th hour is significantly shorter than Group 3 (p < 0.05, n = 3). The longer tumor 
retention time indicates that high HER2-receptor targeting specificity of HER2-PEG-NDs 
greatly avoid uptake by the RES and clearance by blood circulation in contrast to non-
targeted NDs.35
4. CONCLUSIONS
While tons of PA contrast agents for cancerous tumor detection have been proposed, it is 
still facing some problems concerning light stability and long-term toxicity. In this work, 
non-toxic, stable and tageting moiety modified non-fluorescent nanodiamonds were 
successfully developed as a novel in vivo photoacoustic imaging contrast agent and shown to 
facilitate the optical contrast enhancement of breast cancerous tumor contour for effective 
HER2 positive breast cancer diagnosis. The conjugation of anti-HER2 peptide with 
PEGylated NDs was observed to lead to an enhancement in the internalization by HER2 
overexpressing tumor cells (4T1.2 neu) and longer residence time in the tumor region. The 
long-term biocompatibility study of the nanodiamonds after intraperitoneal injection have 
been performed for 12 weeks and repored in our earlier publication, which indicated that the 
NDs administration did not result in any apparent toxicological effects.24 We expect this 
Zhang et al. Page 7













targeting-nanodiamond-PA imaging platform to provide a new oppotunity for sensitive 
detection of cancer tumors and become a promising delivery strategy for anti-cancer drugs.
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Infrared spectra of ND, PEGylated NDs (PEG-NDs), HER2-PEGylated NDs (HER2-PEG-
NDs) and anti-HER2 peptide.
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Particle size distribution of (a) NDs, (b) PEG-NDs and (c) HER2-PEG-NDs.
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Particle size distribution of (a) NDs, (b) PEG-NDs and (c) HER2-PEG-NDs.
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Brightfield images of murine breast cancer cells. (a) Non-treated 4T1.2 neu cells, (b) 4T1.2 
neu cells treated with PEG-NDs, (c) Non-treated 4T1.2 cells, (d) 4T1.2 cells treated with 
HER2-PEG-NDs and (e) 4T1.2 neu cells treated with HER2-PEG-NDs.
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PA images of ROI before and at different time points after the injection of NDs and 
photographs of ROI. a) 4T1.2 neu tumor model injected with PEG-NDs, (b) 4T1.2 tumor 
model injected with HER2-PEG-NDs, c) 4T1.2 neu tumor model injected with HER2-PEG-
NDs, and (d) particle retention time in each group.
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Schematic of photoacoustic imaging system.
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Table 1
Measured particle sizes and zeta-potentials of NDs, PEGylated NDs and HER2 targeting peptide conjugated 
PEG-NDs.
Particles Diameter (nm) Zeta-potentials (mV)
NDs 38.3 ± 0.03 −36.49 ± 1.27
PEG-NDs 56.0 ± 0.1 −33.07 ± 1.44
HER2-PEG-NDs 92.1 ± 1.077 −22.67 ± 1.07
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